N/A N=176 Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence
Eveningness/Sleep
Primary: Total Sleep Time (TST) Average on Weeknights Via Daily Sleep Diary — 24.72; 13.02 Minutes — p=0.34
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Glasses for Adolescent Delayed Sleep-Wake Phase Disorder
Delayed Sleep-Wake Phase Disorder
Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours
N/A N=33 Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Non-visual Photoreception
Primary: Melatonin Suppression — 71.4; 70.1; 54.3; 32.5 Percentage suppression — p=0.73
N/A N=142 Delayed Sleep Timing in Teens Study
Delayed Sleep Phase
Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018
N/A N=15 Blue Blockers at Night and Insomnia Symptoms
Insomnia · Sleep
Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale
N/A N=46 Individually Tailored Lighting System to Improve Sleep in Older Adults
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
N/A N=25 Sleep Timing and Insulin Resistance in Adolescents With Obesity
Obesity
Primary: Dim Light Melatonin Onset and Offset — 21.33; 8.32 decimal hours
N/A N=16 Sleep Length and Circadian Regulation in Humans
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
N/A N=12 Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
N/A N=845 MTNR1B SNP*Food Timing Interaction on Glucose Control
Non-Diabetic Disorder of Endocrine Pancreas
Primary: Area Under the Curve (AUC) Glucose — 278.84; 268.92; 260.66; 282.21 mg*h/dL
N/A N=11 Ramelteon for a Nap Prior to a Night Shift
Healthy
Primary: Sleep Efficiency — 89.1; 83.3 percent
Phase 4 N=19 Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
Sleep Disorder, Shift-Work
Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05
N/A N=118 Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
N/A N=120 Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Sleep Deprivation · Diabetes · Circadian Dysregulation
Primary: Oral Disposition Index — 11.5 None (Index) — p=.13
N/A N=44 Are Bright Lights and Regulated Sleep Effective Treatment for Depression?
Sleep Phase Rhythm Disturbance · Sleep Deprivation
Primary: 17-Item Hamilton Rating Scale for Depression Score (Independent Evaluator) — 8.66; 10.46 units on a scale
N/A N=20 Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern
Diet-induced Thermogenesis
Primary: Intra-individual Variation in Morning Diet-induced Thermogenesis (DIT) Evaluated by Calorimetric Exam After the Consumption of a Meal at 8:00 am Compared With Evening…
N/A N=7 Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
N/A N=17 Sleep and Circadian Rhythms in Mechanically Ventilated Patients
Respiratory Failure · Critical Illness
Primary: Percentage of Subjects Who Successfully Undergo Continuous Bedside Polysomnography for at Least 24 Hours. — 9; 8; 5 Participants
N/A N=40 Escitalopram Treatment of Night Eating Syndrome
Night Eating Syndrome
Primary: Night Eating Questionnaire — -13.0; -10.6 units on a scale
N/A N=40 Recovery Enhancement and Sleep Training
Sleep · Performance · Mental Health
Primary: Pittsburgh Sleep Quality Index ( PSQI) — 4.941176471; 6.555555556; 4.647058824; 5.833333333 units on a scale
Phase 2 N=549 Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome
Sleep Disorders, Circadian Rhythm
Primary: Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) — 59.30; 39.40; 55.94; 55.12 minutes — p=0.646
N/A N=108 Association Between Food/Nutrient Intake and Sleep Quality in Middle Aged and Older Population
Sleep
Primary: Sleep Quality Assessment 1 (GSS) — 3.4; 8.1; 5.2 score on a scale
Phase 4 N=29 Lemborexant Shift Work Treatment Study
Shift-Work Related Sleep Disturbance
Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884
N/A N=22 Blue Wavelength Light-blocking Glasses in ADHD-Insomnia
Attention Deficit Hyperactivity Disorder · Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Primary: Pittsburgh Sleep Quality Index (PSQI) at 2 Weeks After Baseline — 4.54 units on a scale
N/A N=31 Metabolic Effects of Sleep Extension in People With Obesity
Insulin Resistance · Obesity
Primary: Insulin Sensitivity — -3.8; 0.9 µmol/kgFFM/min
N/A N=12 Sleep to Activate Mood Promotion
Depression · Sleep Quality
Primary: Pittsburgh Sleep Quality Index — 7.0 units on a scale — p=0.37
Phase 3 N=40 The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder
Delayed Sleep Phase Syndrome
Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510
N/A N=11 Insulin Variance Throughout the Day
Insulin Sensitivity
Primary: Difference in Glucose Tolerance Between Morning at 7:00 AM and Evening at 7:00 PM — 163; 203 mg/dl — p=0.02
N/A N=6 A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Enrollments in the Study Over One Year — 4; 2 Participants
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours